By Byron Kaye SYDNEY, Feb 3 (Reuters) - Sleep-breathing device maker ResMed plans to take global a doctor education program aimed at promoting the screening of patients seeking Ozempic-style weight ...

Resmed shares are down a bit today, even though second-quarter results came in ahead of the consensus forecast.

ResMed dominates the global sleep apnea device market, boasting a 50–60% share and a high-margin razor-razor-blade business ...

By Siddhi Mahatole Jan 29 (Reuters) - Medical device maker ResMed on Thursday beat Wall Street estimates for second-quarter profit on the back of strong demand for its devices used to manage sleep ...

Masks and accessories were the standout growth category for Resmed in the second quarter of its fiscal year 2026, with the company reporting a 16% increase in revenue in the United States, Canada and ...

For the quarter ended December 31, 2025, ResMed reported adjusted earnings per share of $2.81, exceeding analyst estimates of $2.73. Revenue increased 11% to $1.4 billion, in line with consensus ...

SAN DIEGO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Resmed (NYSE: RMD, ASX: RMD), the leading health technology company focused on sleep, breathing and care delivered in the home, today announced it has ...

On Thursday, ResMed Inc (NYSE:RMD) reported first-quarter adjusted EPS of $2.20, up 34% year over year, beating the consensus of $2.04. The company reported sales of $1.224 billion, up 11%, beating ...

ResMed Inc (RMD) reports robust financial performance with 11% revenue growth and unveils new product launches amidst ...

RMD is set to report Q2 results on Jan. 29, with revenues likely to jump 8.3% and EPS 10.3% as masks, devices and software drive growth.

Medical device company ResMed (NYSE:RMD) beat Wall Street’s revenue expectations in Q4 CY2025, with sales up 11% year on year ...